openPR Logo
Press release

Thrombocytopenia Market to Exhibit CAGR of 4.69% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight

07-06-2022 05:40 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Thrombocytopenia Market

Thrombocytopenia Market

DelveInsight's "Thrombocytopenia Market" report provides a thorough comprehension of the Thrombocytopenia, historical and forecasted epidemiology, and the Thrombocytopenia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Thrombocytopenia market report also proffers an analysis of recent Thrombocytopenia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs.

To know more about Thrombocytopenia Market report: https://www.delveinsight.com/report-store/thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the vital points from the Thrombocytopenia Market Research Report
• Thrombocytopenia Market is expected to experience considerable growth, and this is attributable to the rise in the Thrombocytopenia patient pool, availability of products, and the anticipated launch of emerging therapies.
• Market players such as Sanofi, Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi, Shionogi & Co., Ltd., Amgen, Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta, Takeda, Argenx, GC Pharma, Omeros Corporation, Biotest, Millennium Pharmaceuticals, Cellphire, Momenta Pharmaceuticals, ILTOO Pharma, Genosco, and several others are involved in developing Thrombocytopenia therapies.
• Thrombocytopenia market might experience significant growth due to the expected launch of upcoming therapies such as Rozanolixizumab (UCB7665); Rilzabrutinib (PRN-1008); BAX930; Efgartigimod (ARGX-113); Cablivi (caplacizumab); Tavalisse/Tavlesse (Fostamatinib); Doptelet (Avatrombopag); Nplate (Romiplostim); and Mulpleta (lusutrombopag), and others.

For additional information on Market Impact by Therapies, visit: https://www.delveinsight.com/report-store/thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Thrombocytopenia is a condition in which the blood has a lower than a normal number of platelets. The condition can be inherited or acquired. Thrombocytopenia causes, sometimes, are not known. The main Thrombocytopenia symptoms include mild-to-severe bleeding. Bleeding can occur inside the body or underneath the skin, or from the skin's surface. As per DelveInsight's analysts, the total number of Thrombocytopenia cases in the 7MM was 1,653,934 in 2020.

The Thrombocytopenia Market Report provides historical as well as forecasted epidemiological analysis segmented into:
• Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP)
• Prevalent Cases of Immune Thrombocytopenia (ITP)
• Prevalent Cases of Thrombocytopenia in Chronic Liver Disease
• Incident Cases of Chemotherapy-induced Thrombocytopenia
• Number of Cases of Heparin-induced Thrombocytopenia
• Total Cases of Thrombocytopenia

Request sample report for more insights @ https://www.delveinsight.com/sample-request/thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Thrombocytopenia Treatment Market
Thrombocytopenia treatment depends on its cause and severity. The main goal of Thrombocytopenia treatment is to prevent death and disability caused by bleeding. If the condition is mild, the patient may not need treatment.

One treatment approach is a direct treatment to the etiology of thrombocytopenia. Unfortunately, only in a minority of cases is the etiology of thrombocytopenia exact and the cause found. In a case of severe bleeding, if the thrombocytopenia etiology is not known but not thought to be immunologic, platelet transfusion can be used to proffer an immediate platelet increase.
Patients with inherited thrombocytopenia have been treated with platelet transfusions. The option of allogeneic stem cell transplantation is reserved for inherited thrombocytopenia with a high risk of marrow failure or a rising risk of acute leukemia.
Many Immune Thrombocytopenia cases (ITP) can be left untreated, and spontaneous remission in children is common. If therapy is required, the first-line treatment option is generally corticosteroids. The most effective second-line treatment option is splenectomy. Further, second-line treatment options with documented evidence of efficacy comprise various agents: azathioprine, cyclosporine, cyclophosphamide, danazol, dexamethasone, vinca alkaloids, mycophenolate mofetil, rituximab, and thrombopoietin-receptor agonists.

The use of thrombopoietin-receptor agonists is an effective and safe second-line treatment strategy. Two thrombopoietin-receptor agonists were authorized to treat chronic ITP in adults by the US Food and Drug Administration (FDA) in 2008 and have been utilized extensively for chronic ITP treatment in relapsed and refractory patients. These were romiplostim, a thrombopoietin mimetic formed from peptides (peptibody), and eltrombopag (a small molecule, non-peptide).
The mainstay of Thrombotic Thrombocytopenic Purpura (TTP) treatment is plasmapheresis with plasma replacement. Other treatment modalities in non-responders to plasmapheresis include immune-suppression, not limited to high dose steroids and B-cell depleting agents (e.g., rituximab).

Thrombocytopenia Emerging Therapies Along with Key Players

Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved soon. The major key players enumerated below can create a significant positive shift in Thrombocytopenia market size.
• Rozanolixizumab (UCB7665): UCB Biopharma
• Rilzabrutinib (PRN-1008): Principia Biopharma
• TAK-755 (BAX930/SHP655): Baxalta/Takeda
• Efgartigimod (ARGX-113): Argenx
• GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma
• Narsoplimab (OMS721): Omeros Corporation
• BT-595: Biotest
• TAK-079: Millennium Pharmaceuticals/Takeda
• Thrombosomes: Cellphire
• M254 (Hypersialylated IgG): Momenta Pharmaceuticals
• BIVV020: Sanofi
• Interleukin 2: ILTOO Pharma
• SKI-O-703: Genosco (Subsidiary of Oscotec)
And others.

Concluding thoughts on Thrombocytopenia Market Growth: https://www.delveinsight.com/report-store/thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Thrombocytopenia Market Drivers
• More efficacious therapies - Emerging therapies with novel mechanisms of action target the different patient groups of thrombocytopenia and improved drug delivery mechanisms to increase patient compliance.
• Increase in Thrombocytopenia cases - Rise in the cases due to various risk factors such as rise in chemotherapy use, chronic liver disease, and others.
• High chances of drug approvals - The most common type of thrombocytopenia is ITP, which is highly prevalent. Whereas CIT (Chemotherapy-Induced Thrombocytopenia) occurs in patients with cancer due to chemotherapy and radiation treatment. Thrombocytopenia in patients with CLD is growing rapidly, increasing cases of HCV infections among them. These areas may lead to approval of the upcoming therapies with an intent to boost the market.
• Increase in patient compliance - Novel therapies for the treatment of refractory patients. The vast risk factors causing thrombocytopenia offers an excellent opportunity for emerging therapies to target specific disease populations.
• Robust pipeline - Identification of new drug targets will boost novel therapies' entry into the Thrombocytopenia market.

Thrombocytopenia Market Barriers
• Economic burden - Strict pricing and reimbursement policies.
• Low disease awareness and delay in diagnosis - Currently, no cure is available for congenital thrombocytopenia.
• Complications associated with current therapies - Adverse events associated with the available therapies such as corticosteroids, which causes mood swings, difficulty sleeping, weight gain, hypertension, diabetes, gastric irritation, skin thinning, and osteoporosis.

To know more about Thrombocytopenia Market Dynamics, click here: https://www.delveinsight.com/report-store/thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Thrombocytopenia Market Insight
• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 10-year forecasted analysis (2018-2030).
• Thrombocytopenia Markets Segmentation: By Geographies and By Thrombocytopenia Therapies (Historical and Forecasted, Current and Upcoming)
• Leading Market Companies investigating its candidates for Thrombocytopenia: Sanofi, Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi, Shionogi & Co., Ltd., Amgen, Novartis, Zenyaku Kogyo, UCB Biopharma, Principia Biopharma, Baxalta, Takeda, Argenx, GC Pharma, Omeros Corporation, Biotest, Millennium Pharmaceuticals, Cellphire, Momenta Pharmaceuticals, ILTOO Pharma, Genosco, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis.
• Case Studies
• KOL's Views
• Analyst's View

Request for a Webex demo of the report@ https://www.delveinsight.com/sample-request/thrombocytopenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1 Key Insights on Thrombocytopenia
2 Executive Summary of Thrombocytopenia
3 Thrombocytopenia Market Overview at a Glance
4 Disease Background and Overview: Thrombocytopenia
5 Thrombocytopenia Patient Journey
6 Thrombocytopenia Epidemiology and Patient Population
6.1 United States Epidemiology
6.2 EU5 Countries Epidemiology
6.2.1 Germany
6.2.2 France
6.2.3 Italy
6.2.4 Spain
6.2.5 United Kingdom
6.3 Japan Epidemiology
7 Thrombocytopenia Treatment
8 Thrombocytopenia Unmet Needs
9 Thrombocytopenia Marketed Drugs
9.1 Cablivi (Caplacizumab/ALX-0081): Sanofi (Ablynx)
9.2 Tavalisse (Fostamatinib): Rigel Pharmaceuticals/Kissei Pharmaceutical
9.3 Doptelet (Avatrombopag): Sobi (Dova Pharmaceuticals)
9.4 Mulpleta/Mulpleo (Lusutrombopag): Shionogi & Co., Ltd.
9.5 Nplate (Romiplostim, AMG-531): Amgen
9.6 Promacta (eltrombopag): Novartis
9.7 Rituxan (rituximab): Zenyaku Kogyo
10 Thrombocytopenia Emerging Drugs
10.1 Key Cross Competition
10.2 Rozanolixizumab (UCB7665): UCB Biopharma
10.3 Rilzabrutinib (PRN-1008): Principia Biopharma
10.4 TAK-755 (BAX930/SHP655): Baxalta/Takeda
10.5 Efgartigimod (ARGX-113): Argenx
10.6 GC5101B (GC5107A, IV-Globulin SN Inj. 10%): GC Pharma
10.7 Narsoplimab (OMS721): Omeros Corporation
10.8 BT-595: Biotest
10.9 TAK-079: Millennium Pharmaceuticals/Takeda
10.10 Thrombosomes: Cellphire
10.11 M254 (Hypersialylated IgG): Momenta Pharmaceuticals
10.12 BIVV020: Sanofi
10.13 Interleukin 2: ILTOO Pharma
10.14 SKI-O-703: Genosco (Subsidiary of Oscotec)
11 7MM Thrombocytopenia Market Analysis
12 United States Thrombocytopenia Market Outlook
13 EU-5 Thrombocytopenia Market Outlook
13.1 Germany Market Size
13.2 France Market Size
13.3 Italy Market Size
13.4 Spain Market Size
13.5 United Kingdom Market Size
14 Japan Thrombocytopenia Market Outlook
15 Thrombocytopenia Market Drivers
16 Thrombocytopenia Market Barriers
17 SWOT Analysis
18 Reimbursement and Thrombocytopenia Market Access
19 Appendix
20 DelveInsight Capabilities
21 Disclaimer
22 About DelveInsight

Related Reports:
Metastatic Bone Pain Pipeline https://www.delveinsight.com/report-store/metastatic-bone-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

"Metastatic Bone Pain Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Bone Pain market. A detailed picture of the Metastatic Bone Pain pipeline landscape is provided, which includes the disease overview and Metastatic Bone Pain treatment guidelines.

Primordial Dwarfism Market https://www.delveinsight.com/report-store/primordial-dwarfism-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's "Primordial Dwarfism Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Primordial Dwarfism, historical and forecasted epidemiology as well as the Primordial Dwarfism market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Breast Pumps Market
https://www.delveinsight.com/report-store/breast-pumps-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Breast Pumps Market By Technology Type (Manual, Electric, And Battery), By Sales Channel (Online And Offline), and by geography are expected to grow at a steady CAGR forecast till 2027 owing to surge in the number of employed mothers and technological advancements in the product offering.

Hyperuricemia Market
https://www.delveinsight.com/report-store/hyperuricemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's "Hyperuricemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hyperuricemia, historical and forecasted epidemiology as well as Hyperuricemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Helicobacter Pylori (H. pylori) Infection Market
https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's "Helicobacter Pylori (H. pylori) Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Helicobacter Pylori (H. pylori) Infection, historical and forecasted epidemiology as well as the Helicobacter Pylori (H. pylori) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

AIDS Dementia- Market
https://www.delveinsight.com/report-store/aids-dementia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's "AIDS Dementia- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the AIDS Dementia, historical and forecasted epidemiology as well as the AIDS Dementia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Thrombocytopenia Market to Exhibit CAGR of 4.69% for the Study Period of 2018-2030, Backed by Expected Launch of Emerging Therapies, Reports DelveInsight here

News-ID: 2672225 • Views:

More Releases from DelveInsight Business Research

Musculoskeletal pain Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Mesoblast, Regenron, Teva, Taiwan Liposome, Eli Lilly, Axsome Therapeutics, Biosplice Therapeutics
Musculoskeletal pain Market Forecasted to Surge in Coming Years, 2023-2032 Analy …
The Musculoskeletal pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Musculoskeletal pain pipeline products will significantly revolutionize the Musculoskeletal pain market dynamics. DelveInsight's "Musculoskeletal pain Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Musculoskeletal pain, historical and forecasted epidemiology as well as the Musculoskeletal pain market trends in the United
Vitiligo Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Pfizer, Clinuvel, Inc., Clinuvel Pharmaceuticals, Bioniz Therapeutics, TAGCyx Biotech
Vitiligo Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Preva …
(Albany, USA) DelveInsight's "Vitiligo Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vitiligo, historical and forecasted epidemiology as well as the Vitiligo market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Vitiligo market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vitiligo pipeline products will significantly
Benign Prostatic Hyperplasia Treatment Market 2032: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma,
Benign Prostatic Hyperplasia Treatment Market 2032: FDA Approvals, Clinical tria …
(Albany. USA) DelveInsight's "Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic
Leukocyte Adhesion Deficiency Treatment Market 2034: FDA Approvals, Clinical trials, Therapies, Prevalence and Companies by DelveInsight | Rocket Pharmaceuticals, Inc., Orpha Labs
Leukocyte Adhesion Deficiency Treatment Market 2034: FDA Approvals, Clinical tri …
(Albany, USA) DelveInsight's "Leukocyte Adhesion Deficiency Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Leukocyte Adhesion Deficiency, historical and forecasted epidemiology as well as the Leukocyte Adhesion Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Leukocyte Adhesion Deficiency market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore,

All 5 Releases


More Releases for Thrombocytopenia

What is behind the Rise of the Immune Thrombocytopenia Market?
The global immune thrombocytopenia market is likely to derive growth from recent advancements in treatment methods of the disease. According to a report published by Fortune Business Insights, titled “ Immune Thrombocytopenia Market Size, Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2019-2026,” the
Immune Thrombocytopenia Drugs Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Immune Thrombocytopenia Drugs Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Immune Thrombocytopenia Drugs players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Immune Thrombocytopenia Drugs with respect
Global Thrombocytopenia Management IMarket Trend and Forecast 2025
This study focuses on the production side and consumption side of Thrombocytopenia Management, presents the global Thrombocytopenia Management market size by manufacturers, regions, type and application, history breakdown data from 2013 to 2018, and forecast to 2025. In terms of production side, this report researches the Thrombocytopenia Management capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and product type. Request Sample Copy of Report@
Thrombocytopenia Treatment Market Outlook, and Opportunity Analysis, 2018–2026
Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The most common ineffective production of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can be inherited or acquired. In 2014, According to a research article published in Professional
Global Thrombocytopenia Treatment Market Dynamics
Thrombocytopenia is a disorder in which a patient has low level of platelets in the blood. The major causes of thrombocytopenia are inefficient production of platelets, platelet splenic sequestration, and accelerative destruction of platelets. The most common ineffective production of thrombocytes are due bone marrow failure syndrome such as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can be inherited or acquired. In 2014, According to a research article published in Professional
Thrombocytopenia Therapeutics Market Forecast Research Reports Offers Key Insigh …
Platelets in the blood enable blood to clot. Abnormally low count of platelets in the blood as a result of presence of any disease or disorder is referred to as thrombocytopenia. Thus, presence of thrombocytopenia in an individual leads to delayed or no blood clotting. The global thrombocytopenia therapeutics market is expected to expand significantly in the near future, owing to high incidence of thrombocytopenia and rising awareness about its